Kiniksa Pharmaceuticals Ltd
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | KINIKSA PHARMACEUTICALS, LTD. | |
|---|---|---|
| | | |
| Date: February 28, 2024 | By: | /s/ Sanj K. Patel |
| | | Sanj K. Patel |
| | | Chief Executive Officer and Chairman of the Board of Directors |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ Sanj K. Patel | | Chief Executive Officer and Chairman of the Board of Directors (principal executive officer) | | February 28, 2024 |
| Sanj K. Patel | | | | |
| | | | | |
| /s/ Mark Ragosa | | Chief Financial Officer (principal financial officer) | | February 28, 2024 |
| Mark Ragosa | | | | |
| | | | | |
| /s/ Michael R. Megna | | Group VP, Finance and Chief Accounting Officer (principal accounting officer) | | February 28, 2024 |
| Michael R. Megna | | | | |
| | | | | |
| /s/ Felix J. Baker | | Lead Independent Director | | February 28, 2024 |
| Felix J. Baker | | | | |
| | | | | |
| /s/ Stephen R. Biggar | | Director | | February 28, 2024 |
| Stephen R. Biggar | | | | |
| | | | | |
| /s/ G. Bradley Cole | | Director | | February 28, 2024 |
| G. Bradley Cole | | | | |
| | | | | |
| /s/ Richard S. Levy | | Director | | February 28, 2024 |
| Richard S. Levy | | | | |
| | | | | |
| /s/ Thomas R. Malley | | Director | | February 28, 2024 |
| Thomas R. Malley | | | | |
| | | | | |
| /s/ Tracey L. McCain | | Director | | February 28, 2024 |
| Tracey L. McCain | | | | |
| | | | | |
| /s/ Kimberly J. Popovits | | Director | | February 28, 2024 |
| Kimberly J. Popovits | | | | |
| | | | | |
| /s/ Barry D. Quart | | Director | | February 28, 2024 |
| Barry D. Quart | | | | |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| | ||
|---|---|---|
| | Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | | F-2 |
| Consolidated Balance Sheets | | F-5 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) | | F-6 |
| Consolidated Statements of Shareholders’ Equity | | F-7 |
| Consolidated Statements of Cash Flows | | F-8 |
| Notes to Consolidated Financial Statements | | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.